If you’d invested in: Indivior and Next
Drugmaker Indivior is on the up, while retailer Next, once a favourite with investors, has lost its way.
If only
Indivior (LSE: INDV) is a pharmaceutical company that specialises in producing Suboxone, a prescription drug for the treatment of patients who are dependent on opioids. The firm operates in 40 countries worldwide. It was set up in 1994 as the pharmaceuticals division of consumer goods giant Reckitt Benckiser, but was spun off in December 2014 and listed as Indivior on the London Stock Exchange.In its first year as a public company, it made an operating profit of $346m on revenue of $1bn. Over the last year, the shares have risen by more than 130%.
Be glad you didn't
Fashion retailer Next (LSE: NXT) was once a favourite with investors. Between 2008 and late 2015, its shares rose by almost ten times. But since then, the company has lost its way as retail trends change. Last year proved difficult as customers deserted the chain, leading to multiple profit warnings. There's no relief in sight: last month, the firm warned that 2017 will be even tougher. The share price has slumped by over 40% in the past year.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Ben studied modern languages at London University's Queen Mary College. After dabbling unhappily in local government finance for a while, he went to work for The Scotsman newspaper in Edinburgh. The launch of the paper's website, scotsman.com, in the early years of the dotcom craze, saw Ben move online to manage the Business and Motors channels before becoming deputy editor with responsibility for all aspects of online production for The Scotsman, Scotland on Sunday and the Edinburgh Evening News websites, along with the papers' Edinburgh Festivals website.
Ben joined MoneyWeek as website editor in 2008, just as the Great Financial Crisis was brewing. He has written extensively for the website and magazine, with a particular emphasis on alternative finance and fintech, including blockchain and bitcoin.
As an early adopter of bitcoin, Ben bought when the price was under $200, but went on to spend it all on foolish fripperies.
-
How to profit from defence stocks beyond EuropeOpinion Tom Bailey, head of research for the Future of Defence Indo-Pac ex-China UCITS ETF, picks three defence stocks where he'd put his money
-
Why the Waspi women are wrong'Opinion Compensation for the Waspi women would mean using an unaffordable sledgehammer to crack a nut, says David Prosser
-
Defeat into victory: the key to Next CEO Simon Wolfson's successOpinion Next CEO Simon Wolfson claims he owes his success to a book on military strategy in World War II. What lessons does it hold, and how did he apply them to Next?
-
Next’s results stand out against a tough retail backdropAnalysis FTSE 100 retailer Next is dealing well with the tough conditions on the high street, with rising profits and a plan that's working. Rupert Hargreaves looks at the numbers.
-
Why Next is the only retailer I’d want to own in my portfolioNews The retail sector is brutally competitive. But high street stalwart Next is exploiting and building on its significant competitive advantages, says Rupert Hargreaves.
-
Next shares soar as sales smash expectations – is the stock a buy?News High street and online retailer Next has reported a big rise in sales and profits. John Stepek looks at its performance and asks if it's worth buying Next shares.
-
Little cheer on the high streetFeatures Profit warnings from Debenhams and Mothercare are more evidence that traditional retailers are fighting a losing battle against nimbler online competitors, says Ben Judge.
-
Indivior’s miracle drug wears offFeatures Indivior’s opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Gråhns reports.
-
Next: Out of fashion
Features Clothing retailer Next has released gloomy results, yet the firm’s shares rallied strongly. Why? Ben Judge reports.
-
Next faces its toughest year since 2008
Features The clothing retailer has long been a favourite of long-term investors, but now Next is facing tough times.
